| Sarkis John Chobanian, MD | |
|
1311 Dowell Springs Blvd, Ste 300, Knoxville, TN 37909-2454 | |
| (865) 588-5121 | |
| (865) 588-2126 |
| Full Name | Sarkis John Chobanian |
|---|---|
| Gender | Male |
| Speciality | Gastroenterology |
| Experience | 47 Years |
| Location | 1311 Dowell Springs Blvd, Knoxville, Tennessee |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1730114141 | NPI | - | NPPES |
| Q008654 | Medicaid | TN |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207RG0100X | Internal Medicine - Gastroenterology | MD17781 (Tennessee) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Physicians Regional Medical Center | Powell, TN | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Gastrointestinal Associates Pc | 9739132705 | 30 |
News Archive
Intellect Neurosciences, Inc., a biopharmaceutical company with an internal preclinical and clinical-stage pipeline and multiple licenses with major pharmaceutical companies covering products in late-stage clinical trials, announced that it has obtained a draft pharmacokinetic report from its completed Phase 1b trial for its lead Alzheimer's candidate, OX1. The Company previously reported on the safety aspects of the trial, which demonstrated that OX1 is safe and well tolerated at all dose levels tested.
A new study out of Boston's Children's Hospital has used the gene-editing tool CRISPR-Cas9 to explore the fatal genetic condition called facioscapulohumeral dystrophy (FSHD, one of the family of muscular dystrophies), and to test out the potential utility of various genes involved in this disorder. The research is published in the journal Science Translational Medicine.
Try to schedule your screening mammogram during the first week of your menstrual cycle. It might make breast cancer screening more accurate for pre-menopausal women who choose to have regular mammograms. This recommendation comes from an article published online December 3 in Radiology by Diana Miglioretti, PhD, a senior investigator at Group Health Research Institute.
GTx, Inc. (Nasdaq: GTXI), today announced that following a planned safety review, an independent Data Safety Monitoring Board (DSMB) has recommended that the company continue as planned the pivotal Phase III clinical trial evaluating toremifene 20 mg for the prevention of prostate cancer in men with high grade prostatic intraepithelial neoplasia (PIN), a precancerous lesion of the prostate.
› Verified 1 days ago
| Entity Name | Gastrointestinal Associates Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1780695999 PECOS PAC ID: 9739132705 Enrollment ID: O20050302000341 |
News Archive
Intellect Neurosciences, Inc., a biopharmaceutical company with an internal preclinical and clinical-stage pipeline and multiple licenses with major pharmaceutical companies covering products in late-stage clinical trials, announced that it has obtained a draft pharmacokinetic report from its completed Phase 1b trial for its lead Alzheimer's candidate, OX1. The Company previously reported on the safety aspects of the trial, which demonstrated that OX1 is safe and well tolerated at all dose levels tested.
A new study out of Boston's Children's Hospital has used the gene-editing tool CRISPR-Cas9 to explore the fatal genetic condition called facioscapulohumeral dystrophy (FSHD, one of the family of muscular dystrophies), and to test out the potential utility of various genes involved in this disorder. The research is published in the journal Science Translational Medicine.
Try to schedule your screening mammogram during the first week of your menstrual cycle. It might make breast cancer screening more accurate for pre-menopausal women who choose to have regular mammograms. This recommendation comes from an article published online December 3 in Radiology by Diana Miglioretti, PhD, a senior investigator at Group Health Research Institute.
GTx, Inc. (Nasdaq: GTXI), today announced that following a planned safety review, an independent Data Safety Monitoring Board (DSMB) has recommended that the company continue as planned the pivotal Phase III clinical trial evaluating toremifene 20 mg for the prevention of prostate cancer in men with high grade prostatic intraepithelial neoplasia (PIN), a precancerous lesion of the prostate.
› Verified 1 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Sarkis John Chobanian, MD Po Box 59002, Knoxville, TN 37950-9002 Ph: (865) 588-5121 | Sarkis John Chobanian, MD 1311 Dowell Springs Blvd, Ste 300, Knoxville, TN 37909-2454 Ph: (865) 588-5121 |
News Archive
Intellect Neurosciences, Inc., a biopharmaceutical company with an internal preclinical and clinical-stage pipeline and multiple licenses with major pharmaceutical companies covering products in late-stage clinical trials, announced that it has obtained a draft pharmacokinetic report from its completed Phase 1b trial for its lead Alzheimer's candidate, OX1. The Company previously reported on the safety aspects of the trial, which demonstrated that OX1 is safe and well tolerated at all dose levels tested.
A new study out of Boston's Children's Hospital has used the gene-editing tool CRISPR-Cas9 to explore the fatal genetic condition called facioscapulohumeral dystrophy (FSHD, one of the family of muscular dystrophies), and to test out the potential utility of various genes involved in this disorder. The research is published in the journal Science Translational Medicine.
Try to schedule your screening mammogram during the first week of your menstrual cycle. It might make breast cancer screening more accurate for pre-menopausal women who choose to have regular mammograms. This recommendation comes from an article published online December 3 in Radiology by Diana Miglioretti, PhD, a senior investigator at Group Health Research Institute.
GTx, Inc. (Nasdaq: GTXI), today announced that following a planned safety review, an independent Data Safety Monitoring Board (DSMB) has recommended that the company continue as planned the pivotal Phase III clinical trial evaluating toremifene 20 mg for the prevention of prostate cancer in men with high grade prostatic intraepithelial neoplasia (PIN), a precancerous lesion of the prostate.
› Verified 1 days ago
Corey Cudzilo, M.D. Gastroenterology Medicare: Accepting Medicare Assignments Practice Location: 2240 Sutherland Ave, Suite 103, Knoxville, TN 37919 Phone: 865-588-8831 Fax: 865-588-8841 | |
Dr. Joshua Weber Todd, M.D. Gastroenterology Medicare: May Accept Medicare Assignments Practice Location: 1819 W Clinch Ave, Suite 108, Knoxville, TN 37916 Phone: 865-546-5111 Fax: 865-541-4018 | |
Rasmi Ajit, MD Gastroenterology Medicare: Accepting Medicare Assignments Practice Location: 9330 Park West Blvd Ste 402, Knoxville, TN 37923 Phone: 865-690-3003 Fax: 865-374-2143 | |
Dr. Spencer Pugh, M.D. Gastroenterology Medicare: May Accept Medicare Assignments Practice Location: 1924 Alcoa Hwy, Department Of Medicine U-114 Gsm, Utmck, Knoxville, TN 37920 Phone: 865-305-9340 Fax: 865-305-9144 | |
Saji Eapen, MD Gastroenterology Medicare: Accepting Medicare Assignments Practice Location: 1415 Old Weisgarber Rd, Suite 200, Knoxville, TN 37909 Phone: 865-934-5800 Fax: 865-934-5801 | |
Jeffrey W Robinson, MD Gastroenterology Medicare: Accepting Medicare Assignments Practice Location: 6600 Nightingale Ln, Knoxville, TN 37909 Phone: 865-632-5885 | |
Dr. Mark D Anderson, MD Gastroenterology Medicare: Accepting Medicare Assignments Practice Location: 1928 Alcoa Hwy, B100, Knoxville, TN 37920 Phone: 865-544-6570 Fax: 865-544-6576 |